Patents by Inventor Ann M. Moriarty
Ann M. Moriarty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9222070Abstract: T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen.Type: GrantFiled: July 24, 2007Date of Patent: December 29, 2015Assignee: Janssen Pharmaceuticals, Inc.Inventors: Didier J. Leturcq, Ann M. Moriarty, Michael R. Jackson, Per A. Peterson, Jon M. Richards
-
Publication number: 20090004142Abstract: T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen.Type: ApplicationFiled: July 24, 2007Publication date: January 1, 2009Inventors: Didier J. Leturcq, Ann M. Moriarty, Michael R. Jackson, Per A. Peterson, Jon M. Richards
-
Patent number: 7326569Abstract: This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.Type: GrantFiled: September 3, 2002Date of Patent: February 5, 2008Assignee: The Scripps Research InstituteInventors: Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
-
Patent number: 6828150Abstract: The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules and assisting molecules such as co-stimulatory molecules. The matrices can be used to activate CD8+ T-cells to produce cytokines and become cytotoxic.Type: GrantFiled: October 8, 2002Date of Patent: December 7, 2004Assignee: The Scripps Research InstituteInventors: Zeling Cai, Jonathan Sprent, Anders Brunmark, Michael Jackson, Per A. Peterson, Alain Luxembourg, Didier J. Leturcq, Ann M. Moriarty
-
Publication number: 20040071671Abstract: T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naïve cytotoxic T lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCS; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen.Type: ApplicationFiled: November 7, 2002Publication date: April 15, 2004Inventors: Didier J. Leturcq, Ann M. Moriarty, Michael R. Jackson, Per A. Peterson, Jon M. Richard
-
Publication number: 20030138946Abstract: The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules and assisting molecules such as co-stimulatory molecules. The matrices can be used to activate CD8+ T-cells to produce cytokines and become cytotoxic.Type: ApplicationFiled: October 8, 2002Publication date: July 24, 2003Applicant: The Scripps Research InstituteInventors: Zeling Cai, Jonathan Sprent, Anders Brunmark, Michael Jackson, Per A. Peterson, Alain Luxembourg, Didier J. Leturcq, Ann M. Moriarty
-
Patent number: 6461867Abstract: Materials and methods of activating T lymphocytes with specificity for particular antigenic peptides are described, as well as the use of activated T lymphocytes in vitro for the treatment of a variety of disease conditions. In particular, a synthetic antigen presenting matrix for activating T lymphocytes to a specific peptide is described.Type: GrantFiled: September 8, 1997Date of Patent: October 8, 2002Assignee: The Scripps Research InstituteInventors: Zeling Cai, Jonathan Sprent, Anders Brunmark, Michael Jackson, Per A. Peterson, Alain Luxembourg, Didier J. Leturcq, Ann M. Moriarty
-
Patent number: 6444206Abstract: This invention provides hybridoma cell lines producing monoclonal antibodies which inhibit CD14 mediated cell activation. Monoclonal antibodies produced by these cell lines also are provided. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent disorders with CD14 mediated cell activation, such as sepsis.Type: GrantFiled: October 13, 1998Date of Patent: September 3, 2002Assignee: The Scripps Research InstituteInventors: Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
-
Patent number: 5820858Abstract: This invention provides monoclonal antibodies that bind to the cell surface CD14 receptor and soluble CD14 receptor. The antibodies are useful for the detection of the presence of cell surface and soluble CD14 in a sample. Chimeric and CDR grafted antibodies generated from the above monoclonal antibodies are further provided. Pharmaceutical compositions containing the above biological compositions are provided. These are useful to treat and prevent LPS-associated disorders, such as sepsis.Type: GrantFiled: January 23, 1995Date of Patent: October 13, 1998Assignee: The Scripps Research InstituteInventors: Didier J. Leturcq, Ann M. Moriarty, Richard J. Ulevitch, Peter S. Tobias, John C. Mathison
-
Patent number: 5534405Abstract: Cloning and expression vectors for hepatitis B HBxAg, cell cultures containing those vectors, polypeptides related to HBxAg, and diagnostic systems and methods for assaying for the presence of HBxAg and anti-HBxAg antibodies in a body sample are disclosed.Type: GrantFiled: November 18, 1994Date of Patent: July 9, 1996Assignee: The Scripps Research InstituteInventors: Ann M. Moriarty, Hannah Alexander, Richard A. Lerner
-
Patent number: 5183734Abstract: Antibodies that immunoreact with the hepatitis B virus HBxAg antigen and with HBxAg polypeptides, as well as diagnostic system and methods for assaying for the presence of HBxAg and anti-HBxAg antibodies in a body sample are disclosed.Type: GrantFiled: July 17, 1990Date of Patent: February 2, 1993Assignee: The Scripps Research InstituteInventor: Ann M. Moriarty
-
Patent number: 5143726Abstract: Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.Type: GrantFiled: November 20, 1989Date of Patent: September 1, 1992Assignee: The Scripps Research InstituteInventors: George B. Thornton, Ann M. Moriarty, David R. Milich, Alan McLachlan
-
Patent number: 4942125Abstract: Cloning and expression vectors for hepatitis B HBxAg, cell cultures containing those vectors, polypeptides related to HBxAg and diagnostic systems and methods for assaying for the presence of HBxAg and anti-HBxAg antibodies in a body sample are disclosed.Type: GrantFiled: May 26, 1987Date of Patent: July 17, 1990Assignee: Scripps Clinic and Research FoundationInventor: Ann M. Moriarty
-
Patent number: 4882145Abstract: Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.Type: GrantFiled: October 7, 1987Date of Patent: November 21, 1989Assignee: Scripps Clinic and Research FoundationInventors: George B. Thornton, Ann M. Moriarty, David R. Milich, Alan McLachlan
-
Patent number: 4818527Abstract: Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.Type: GrantFiled: December 9, 1986Date of Patent: April 4, 1989Assignee: Scripps Clinic and Research FoundationInventors: George B. Thornton, Ann M. Moriarty, David R. Milich, Alan McLachlan
-
Patent number: 4777240Abstract: Cloning and expression vectors for hepatitis B HBxAg, cell cultures containing those vectors, and diagnostic systems and methods for assaying for the presence of HBxAg and anti-HBxAg in a body sample are disclosed.Type: GrantFiled: September 7, 1984Date of Patent: October 11, 1988Assignee: Scripps Clinic and Research FoundationInventors: Ann M. Moriarty, Hannah Alexander, Richard A. Lerner